Compositions and methods for producing novel amiRNAs
By modifying specific regions of primary miRNAs and optimizing enzyme processing paths, the generation of highly efficient miRNA constructs is solved, and the problems of cumbersome and low efficiency of generating amiRNAs in existing methods are achieved, achieving high-efficiency targeting efficacy and low cytotoxic therapeutic effects.
Patent Information
- Application Number
- CN202380029879.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-02-07
- Publication Date
- 2024-11-12
AI Technical Summary
The existing amiRNA construct generation methods are cumbersome for high-throughput applications, with low cost and time efficiency, making it difficult to meet the needs of efficient production.
By modifying specific regions of primary miRNAs, including the basal, basal stem and loop regions, amiRNA with enhanced silencing effect is generated, and the processing paths of Drosha and Dicer enzymes are used to optimize nucleotide sequences in combination with RNA folding network server tools to form efficient miRNAs Construct.
The efficient generation and targeting effect of amiRNA is achieved, which significantly improves the silencing effect of targeted mRNA, reduces the cytotoxic effect, and improves the construction and delivery efficiency of therapeutic agents.
Smart Images

Figure CN118946662A_ABST
Abstract
Description
Background Art
[0001] The present invention generally relates to amiRNA (artificial microRNA) technology.
[0002] RNA interference (RNAi) is a biological process in which the expression of a given gene is inhibited by small complementary RNAs. One class of such small RNAs is called microRNAs (miRNAs), which are responsible for silencing hundreds of thousands of genes in all known eukaryotic organisms. miRNAs are derived from the processing of primary miRNAs by specific cellular enzyme complexes.
[0003] The main components of a given primary miRNA are the scaffold and the guide / passenger region. The scaffold is further divided into the base, basal stem, and loop. The specific structures and nucleotide sequences in these regions regulate the efficiency and accuracy of the primary miRNA processing into miRNAs and the subsequent effectiveness of silencing target messenger RNAs (mRNAs).
[0004] The leader / follower region is responsible for targeting a specific mRNA. In most cases, the leader / follower region corresponds to the mature miRNA (also known as miRNA-miRNA* duplex). Figure 1 A schematic diagram depicting the processing of miRNAs from primary miRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs), which can be protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce a stem-loop precursor miRNA (pre-miRNA) of approximately 70 nt, which is further cleaved by the cytoplasmic Dicer ribonuclease in the cytoplasm to generate mature miRNA (guide) and antisense miRNA star (miRNA) products. The mature miRNA (guide) is incorporated into the RNA-induced silencing complex (RISC), which recognizes target mRNAs by imperfect base pairing with the miRNA, and the most common result is translational inhibition or destabilization of the target mRNA (mRNA targeting).
[0005] The principle behind the generation of amiRNA is to produce RNAi molecules with enhanced potency that can potentially target any RNA in the cell. The processing and targeting process is aided by enzyme complexes that already exist in every cell (unlike other methods of regulating gene expression, such as CRISPR / Cas9), making the construction of therapeutic agents more feasible and safe. In addition, amiRNAs can be expressed from RNA polymerase II promoters, resulting in less cytotoxic effects.
[0006] Current methods for generating amiRNA constructs can be cumbersome for high-throughput applications and are cost- and time-inefficient.
[0007] The present invention seeks to address these and other problems. Summary of the invention
[0008] Provided herein are methods for producing or generating one or more amiRNAs; also provided are constructs and compositions that can be used in the methods. The methods and constructs provided in the present disclosure are efficient methods for producing a new generation of amiRNAs.
[0009] Portions of the methods and compositions are set forth in the following description, and portions will be apparent from the description or may be learned by practice of the methods and compositions. The advantages of the methods and compositions will be realized and obtained by the elements and combinations particularly noted in the appended claims. It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and do not limit the methods and compositions claimed.
[0010] Therefore, it is the intention of the present invention not to include any previously known product, process of making a product, or method of using a product in the present invention, so that the applicant reserves the right and hereby discloses a disclaimer of any previously known product, process, or method. It is further noted that the present invention is not intended to include any product, process of making a product, or method of using a product that does not meet the written description and implementation requirements of the USPTO (35 U.S.C. §112, first paragraph) or the EPO (EPC Article 83) within the scope of the present invention, so that the applicant reserves the right and hereby discloses a disclaimer of any previously described product, process of making a product, or method of using a product. In practicing the present invention, it may be advantageous to comply with EPC Article 53(c) and EPC Articles 28(b) and (c). The following is expressly reserved: All rights to expressly exclude implementation of the subject matter of any one or more of the applicant's issued patents in the series of this application or in any other series or in any previously filed application of any third party. Nothing herein shall be considered a commitment. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] In the drawings, in several preferred embodiments of the present invention, the same elements are identified by the same reference numerals.
[0012] Figure 1 is a schematic diagram of the biosynthetic pathway from primary miRNA to miRNA.
[0013] Figure 2Ais a graph showing a silencing assay to evaluate the potency of the novel scaffold compared to miRE and miR155. The higher the potency of the amiRNA, the lower the residual fluorescence; Figure 2B is a table showing the residual fluorescence values of amiRNAs and the corresponding average values.
[0014] Figure 3A is a schematic diagram showing selected primary miRNAs to be modified in specific regions of endogenous Let7a1; and Figure 3B is a schematic diagram showing selected primary miRNAs that were modified in specific regions of amiRNA Let7a1 to obtain novel miRNAs.
[0015] Figure 4 Schematic diagram of recombinant rAAV used to deliver amiRNA in a therapeutic setting. GFP-amiRNA transcription is driven by the ubiquitous CAGG promoter.
[0016] Figure 5 is a Western blot experiment showing reduced PTEN protein levels due to expression of amiRNA targeting PTEN. Three negative controls were included in the experiment: No amiRNA is cells infected with a virus expressing GFP but without amiRNA; Mock is untreated cells; Let7f2_WT is cells infected with an unmodified amiRNA known not to cause any knockdown. Images are representative of three independent experiments. HSP90 is shown as a loading control
[0017] Figure 6 is a graph showing qPCR experiments and the reduction in PTEN transcript levels due to the expression of amiRNA targeting PTEN. Three negative controls were included in the experiment: No amiRNA is cells infected with a virus expressing GFP but without amiRNA; Mock is untreated cells; Let7f2_WT is cells infected with unmodified amiRNA known not to cause any knockdown. The average of three independent biological replicates is plotted; error bars represent standard deviations; t-tests were performed to derive p-values compared to "mock" samples.
[0018] Figure 7 Schematic representation of DROSHA processing of GFP-amiRNA hybrids transcribed from rAAV.
[0019] Figure 8is a graph showing qPCR experiments and the reduction in GFP transcript levels due to DROSHA processing of amiRNA. Three negative controls were included in the experiment: No amiRNA is cells infected with a virus expressing GFP but without amiRNA; Mock is untreated cells; Let7f2_WT is cells infected with unmodified amiRNA known not to cause any knockdown. The mean of three independent biological replicates is plotted; error bars represent standard deviations; t-tests were performed to derive p-values compared to the "Let7f2WT" sample.
[0020] Figures 9A-9B is a graph showing normalized quantification of guide and follower strands derived from novel amiRNAs. As emphasized by the difference in the Y-axis scales, the number of guide strands is much higher than that of follower strands. DETAILED DESCRIPTION
[0021] The above and other features and advantages of the present invention are apparent from the following detailed description of exemplary embodiments read in conjunction with the accompanying drawings. The detailed description and drawings are merely illustrative of the present invention rather than limiting the present invention, the scope of the present invention being defined by the appended claims and their equivalents.
[0022] Embodiments of the present invention will now be described with reference to the accompanying drawings, wherein like reference numerals reflect like elements throughout. The terminology used in the description given herein is not intended to be construed in any limiting or restrictive manner simply because it is used in conjunction with the detailed description of certain specific embodiments of the present invention. Furthermore, embodiments of the present invention may include several novel features, no single feature of which is solely responsible for its desired attributes or is necessary for practicing the invention described herein.
[0023] In the context of describing the present invention, the use of the terms "a", "an", and "the" and similar referents should be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. It should also be understood that the terms "comprises", "comprising", "includes", and / or "including" specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.
[0024] Unless otherwise specified herein, the description of the numerical range herein is intended only to be used as a shorthand method for individually referring to each individual value falling within the range, and each individual value is incorporated into the specification as if it were individually described herein. When accompanied by a numerical value, the word "about" should be interpreted as indicating a deviation from the indicated numerical value up to and including 10%. The use of any and all examples or exemplary language ("for example" or "such as") provided herein is intended only to better illustrate the present invention and, unless otherwise stated, does not limit the scope of the present invention. Any language in the specification should not be interpreted as indicating that any unclaimed element is essential to the practice of the present invention.
[0025] References to "one embodiment," "an embodiment," "an exemplary embodiment," "various embodiments," etc. may indicate that one or more embodiments of the invention described herein may include a particular feature, structure, or characteristic, but not every embodiment must include the particular feature, structure, or characteristic. Furthermore, repeated use of the phrases "in one embodiment" or "in an exemplary embodiment" does not necessarily refer to the same embodiment, although they may.
[0026] As used herein, the term "method" refers to ways, means, techniques, and procedures for accomplishing a given task, including but not limited to those known to practitioners in the fields of chemistry, pharmacology, biology, biochemistry, and medicine or readily developed from known ways, means, techniques, and procedures. Unless expressly stated otherwise, it is not intended that any method or aspect set forth herein be interpreted as requiring that its steps be performed in a particular order. Therefore, when a method claim does not specifically state in the claim or description that the steps are limited to a particular order, it is not intended in any way to infer an order. This applies to any possible non-explicit basis for interpretation, including logical issues regarding the arrangement of steps or operational flows, simple meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
[0027] definition
[0028] As used herein, "nucleic acid" refers to a polynucleotide (or oligonucleotide) and includes a single-stranded or double-stranded polymer of deoxyribonucleotides or ribonucleotide bases, unless otherwise limited, including known analogs having the basic properties of natural nucleotides, i.e., they hybridize with single-stranded nucleic acids (e.g., peptide nucleic acids) in a manner similar to naturally occurring nucleotides. Nucleic acids may also include fragments and modified nucleotides.
[0029] As used herein, "nucleic acid construct" or "construct" refers to an isolated polynucleotide introduced into a host cell. The construct may include any combination of deoxyribonucleotides, ribonucleotides and / or modified nucleotides. The construct may be transcribed to form RNA, wherein the RNA may be capable of forming double-stranded RNA and / or a hairpin structure. The construct may be expressed in a cell, or isolated or synthetically produced. The construct may also include a promoter, or other sequences that facilitate the manipulation or expression of the construct.
[0030] As used herein, "microRNA" (also interchangeably referred to herein as "miRNA" or "miR") refers to an oligoribonucleic acid that regulates the expression of a polynucleotide comprising a target sequence transcript. In general, microRNAs (miRNAs) are noncoding RNAs of approximately 21 nucleotides (nt) in length that have been identified in a variety of organisms, including animals and plants (Lagos-Quintana et al., Science 294:853-858 2001, Lagos-Quintana et al, Curr. Biol. 12:735-739 2002; Lau et al, Science 294:858-862 2001; Lee and Ambros, Science 294:862-864 2001; Llave et al., Plant Cell 14:1 605-1619 2002; Mourelatos et al., Genes. Dev. 16:720-728 2002; Park et al., Curr. Biol. 12:1484-1495 2002; Reinhart et al., Science 294:858-862 2001; Lee and Ambros, Science 294:862-864 2001; Llave et al., Plant Cell 14:1 605-1619 2002; Mourelatos et al., Genes. Dev. 16:720-728 2002; Park et al., Curr. Biol. 12:1484-1495 2002; Reinhart et al., Science 294:858-862 2001; al, Genes. Dev. 16: 1616-1626 2002). The primary transcripts of miRNA genes form hairpin structures, which are processed by multidomain ribonucleases DICER and DROSHA (in animals) or DICER-LIKE1 (DCL1; in plants) to produce miRNA duplexes. As used herein, "pre-microRNA" refers to these miRNA duplexes, in which the foldback includes a "distal stem loop" or "distal SL region" of partially complementary oligonucleotides, and "mature miRNA" refers to the miRNA that is incorporated into the RISC complex after the duplex is unwound. In one embodiment, the miRNA is a region comprising R] to Rn, wherein "n" corresponds to the number of nucleotides in the miRNA. In another embodiment, the miRNA is a region comprising R'i to R'n, wherein "n" corresponds to the number of nucleotides in the miRNA. In one aspect, "n" is in the range of about 15 to about 25 nucleotides, and in another aspect, "n" is about 20 or about 21 nucleotides. The term miRNA is specifically intended to encompass naturally occurring polynucleotides, as well as recombinant or synthetic or artificially produced polynucleotides, or amiRNAs.
[0031] "Small interfering RNA" or "siRNA" refers to an RNA of about 21-25 nucleotides processed from dsRNA by the DICER enzyme (in animals) or the DCL enzyme (in plants). The initial DICER or DCL product is double-stranded, with the two strands typically being 21-25 nucleotides in length and containing two unpaired bases at each 3' end. The strands within the double-stranded siRNA structure separate, and typically one of the siRNAs then associates with the multi-subunit complex RNAi-induced silencing complex (RISC). The typical function of siRNA is to guide RISC to the target based on base pair complementarity. The term siRNA is particularly intended to encompass naturally occurring oligonucleotides as well as recombinant or synthetically produced oligonucleotides.
[0032] The term "silencing" or "silencing molecule" as used herein refers to a specific molecule that can exert an effect on cells in a sequence-specific manner to reduce or silence the expression or function of a target (such as a target gene or protein). Examples of silencing agents include nucleic acid molecules such as naturally occurring or synthetically produced small interfering RNA (siRNA), naturally occurring or synthetically produced microRNA (miRNA), naturally occurring or synthetically produced dsRNA and antisense sequences (including antisense oligonucleotides, hairpin structures and antisense expression vectors), and constructs encoding any of such molecules.
[0033] The term "RNAi efficacy or amiRNA efficacy" used herein refers to the ability of RNA to interfere with or inhibit the expression of a target sequence. RNAi efficacy refers to the ability of a small RNA or other molecule to measurably reduce the expression and / or stability of a molecule carrying a target sequence. "Interference" or "inhibition" expression involves reducing the final product of a gene or sequence, such as the expression or function of an encoded protein or protein, nucleic acid, other biological molecule, or a biological function affected by a target sequence, and therefore includes reducing the number or life span of mRNA transcripts or other target sequences. In some embodiments, small RNA or other molecules guide chromatin modification, thereby inhibiting the expression of a target sequence. It should be understood that the phrase is relative and does not require absolute inhibition (containment) of the sequence. Therefore, in certain embodiments, interference or inhibition of the expression of a target sequence requires that after the application of a small RNA or other molecule (such as a vector or other construct encoding one or more small RNAs), the expression of the target sequence is at least 5%, at least 10%, at least 15%, at least 20%, at least 25% or even more reduced than before the application. Therefore, in some specific embodiments, the expression of the target sequence is reduced by about 30%, about 40%, about 50%, about 60% or more using small RNA or other molecules. In specific examples, small RNA or other molecules can reduce the expression of the target sequence by 70%, 80%, 85%, 90%, 95% or even more.
[0034] As used herein, the phrases "target sequence", "target gene" and "target sequence" are used interchangeably and include DNA, RNA transcribed from such DNA (including pre-mRNA and mRNA) and cDNA derived from such RNA, and may also refer to a polynucleotide comprising a target sequence. The target sequence is used to represent a nucleic acid sequence selected for inhibiting expression, and is not limited to a polynucleotide encoding a polypeptide. The target sequence may include coding regions and non-coding regions, such as long non-coding RNA, promoters, enhancers, terminators, introns, etc. The target sequence may be an endogenous sequence, or may be an introduced heterologous sequence or transgene. The specific hybridization of an oligomeric compound with its target sequence may interfere with the normal function of the nucleic acid. The target sequence includes a sequence that is substantially or completely complementary to the target sequence. This regulation of the target nucleic acid function by a compound that specifically hybridizes with the target nucleic acid is generally referred to as "antisense".
[0035] As used herein, "operably linked" refers to a functional arrangement of elements. A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. In a specific embodiment, the operably linked nucleic acids discussed herein are arranged in a linear concatemer that can be cut into fragments, at least one of which is a small RNA molecule.
[0036] As used herein, the phrase "sequence identity" or "sequence similarity" is the similarity between two (or more) nucleic acid sequences or two (or more) amino acid sequences, expressed as the similarity between the sequences, also referred to as sequence identity or sequence homology. Sequence identity is usually measured as the percentage of identical nucleotides or amino acid residues at corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions.
[0037] Those of ordinary skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible to obtain very significant similarities beyond the ranges provided. Due to the degeneracy of the genetic code, nucleic acid sequences that do not show a high degree of identity can still encode similar amino acid sequences. It should be understood that this degeneracy can be used to change nucleic acid sequences to produce multiple nucleic acid molecules that all encode substantially the same protein. Methods for making such adjustments are well known to those skilled in the art. When using percentages of sequence identity with respect to amino acid sequences, it can be recognized that non-identical residue positions are generally different due to conservative amino acid substitutions, in which amino acid residues are replaced by other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity), and therefore do not change the functional properties of the molecule. When sequences differ due to conservative substitutions, the percentage of sequence identity can be adjusted upward to correct for the conservative nature of the substitution. Sequences that differ due to such conservative substitutions are referred to as having "sequence similarity" or "similarity". Methods for making such adjustments are well known to those skilled in the art. Typically, this involves scoring conservative substitutions as partial mismatches rather than complete mismatches, thereby increasing the percentage of sequence identity.
[0038] Description of Embodiments
[0039] Artificial miRNA (amiRNA) is an important and promising tool for developing new targeted therapies. However, only a few amiRNAs are available to the scientific community. In general, methods for generating amiRNAs include optimizing miRNA processing and miRNA efficacy. In one embodiment, the composition of amiRNAs includes a higher miRNA efficacy than the gold standard amiRNAs miRE and miR155. The reduction in fluorescence in the miRNA efficacy assay is proportional to the efficacy. The mean values of efficacy are represented by the percentage of target reduced compared to the control without amiRNA and include: about 65.86% miR155, about 68.12% miREs, about 70.51% Let7a3_loop, about 75.54% Let7a1_loop, about 75.93% Let7a2_all, about 76.10% Let7c_all, about 76.38% miR26b_all, about 76.91% Let7f2_all, about 77.18% Let7f1_all, about 78.18% Let7a3_all, about 78.31% miR26a1_all, about 80.28% miR26a2_base, and about 80.50% miR26a2_stem.
[0040] The amiRNA can be modified by generating hybrid constructs of the base region, basal stem region and loop region from different endogenous and modified primary miRNAs. Experimental validation can investigate whether the function remains intact. According to one embodiment, the artificial miRNA (amiRNA) disclosed herein can be used as an RNA therapeutic. Experimental validation includes transgenic animal models that a) exhibit the expected phenotype predicted by the loss of target gene function, b) accumulate high levels of precisely processed amiRNA, or c) have reduced levels of the corresponding target RNA.
[0041] In one embodiment, the method for generating amiRNA includes modifying a specific region of a primary miRNA to increase silencing efficacy and target a given target mRNA. In one embodiment, the method includes selecting a group of miRNAs with high expression rates based on miRNA databases including miRbase (https: / / www.mirbase.org / ). The method includes obtaining the sequence of the corresponding primary miRNA and selecting about 100 to about 200 nucleotides of each primary miRNA according to a preservation tool. In one embodiment, the preservation tool includes the "Cons100Verts" tool in the USCS genome browser (http: / / genome.ucsc.edu / ). Then, the method includes modifying the selected primary miRNA in a specific region (including a base region, a base stem region, and a loop region).
[0042] The base modification step generates a single stranded region of at least 9 nucleotides and a GU dinucleotide at positions -13 and -14, respectively, from the Drosha cleavage site. The Drosha cleavage site is for the Drosha ribonuclease III. The base modification step requires mutating the nucleotides in a manner that generates the expected structure of the base. The expected structure generated by the base modification step is checked using the RNA folding web server tool. In one embodiment, the RNA folding web server tool is selected from http: / / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi.
[0043] The base stem step modification produces a double-stranded RNA with a CHC motif and a protrusion at position +8 from the Drosha cleavage site. In one embodiment, the total length of the modified base stem is 11 base pairs or between 9 and 13 base pairs, wherein the optimal length is 11 base pairs. The base stem modification step requires mutating nucleotides in a manner that produces the expected structure of the base stem. The structure produced by the base stem modification step is checked using the RNA folding web server tool.
[0044] The loop modification step requires replacing the endogenous loop region of the primary miRNA with the loop of a miRE, the loop of an amiRNA, or another loop with the same number of nucleotides and a GUG motif at the same position. The structure resulting from the modification was examined using the RNA folding web server tool (http: / / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi).
[0045] The base modification construct, the base stem modification construct and the loop modification construct are operably linked to the primary miRNA into one amiRNA construct. The combination of the base modification step, the base stem modification step and the loop modification step produces an amiRNA with enhanced silencing potency. Figure 3A-3B Shown are the base modification construct, base stem modification construct, and loop modification construct with the primary miRNA Let7a1 to obtain the novel amiRNA Let7a1_all.
[0046] The method of generating artificial miRNA 200 (amiRNA) comprises modifying an endogenous primary miRNA gene 100, such as Figure 3A-3B Modification of the endogenous primary mi-RNA occurs in the loop region 110, the base stem region 114, and the base region 116, while the leader / follower region 112 may or may not be altered. Figure 3B As shown, loop modification step 210 includes improving the precision and efficiency of DICER processing. Dicer ribonuclease generates mature miRNA. Leader / follower step 212 includes targeting specific genes or target sequences. Base stem step 214 includes improving the precision and efficiency of DICER processing. Base step 216 includes improving the precision and efficiency of DROSHA processing.
[0047] Modifications at the nucleotide level are based on known structural determinants, which result in more powerful tools for RNA-mediated gene silencing.
[0048] Example
[0049] The following examples are presented to provide a person of ordinary skill in the art with a complete disclosure and description of how to make and evaluate the compounds, compositions, articles, devices and / or methods claimed herein, which are used for illustration of the present invention and are not intended to limit the scope of the invention as the inventors consider it. However, based on this disclosure, it should be understood by those skilled in the art that many changes may be made to the specific embodiments disclosed without departing from the spirit and scope of the present invention, and still obtain the same or similar results.
[0050] Efforts have been made to ensure accuracy with respect to numbers (eg, amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. or is at ambient temperature, and pressure is at or near atmospheric.
[0051] Example 1
[0052] To validate the method for generating novel amiRNAs, silencing experiments were performed comparing the potency of the novel amiRNAs with the known and widely used amiRNAs miRE and miR155. The experiments were based on targeting a fluorescent gene with the amiRNA; the decrease in fluorescence was proportional to the potency of the amiRNA. Figure 2A-2B As shown, the novel amiRNA caused a greater decrease in fluorescent gene expression and was therefore more potent than miRE and miR155.
[0053] sequence:
[0054] The sequence is a heterologous or synthetic or artificial single-stranded ribonucleic acid (RNA), which includes: (i) a selected primary miRNA and its complement, and (ii) a base region between the selected primary miRNA and its complement, wherein the nucleotide sequence of the base region has at least 75% sequence identity with SEQ ID NO:1.
[0055] The heterologous or synthetic or artificial single-stranded ribonucleic acid (RNA) sequence may include: (i) a selected primary miRNA and its complement, and (ii) a base region and a basal stem between the selected primary miRNA and the loop region, wherein the nucleotide sequences of the base region, the basal stem region and the loop region have at least 75% sequence identity with SEQ ID NO:3-9.
[0056] According to another embodiment, the base region, the base stem region and the loop region have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% identity to the nucleotide sequence of SEQ ID NO: 3-9. According to another embodiment of the present invention, the nucleotide sequence identity of the loop region has at least 75% sequence identity to SEQ ID NO: 10-11.
[0057] According to another embodiment, the nucleotide sequence is identical to or has 100% sequence identity with SEQ ID NO: 1-11.
[0058] In one embodiment, the sequence of the novel amiRNA is shown below. Lowercase nucleotides are modifications made to obtain the desired structure. The green labeled sequence is the leader / follower duplex; such regions can be altered to target almost any mRNA or RNA transcript.
[0059] miR26a2_stem: SEQ ID NO: 1
[0060] CCTGTCGGAGCCAAGGACAGAAAGCTCCCATAGAGGCTGTctCcccaggaattataatgcttatctaCTGTTTCCATCTGTGAGGtagataagcattataattcctagGGcGGCAGCTGATGGTCCGCCGCCGGAAACAGAGATGGCCTCC
[0061] miR26a2_base: SEQ ID NO: 2
[0062] CCTGTCGGAGCCAAGGACAGAAAGCTCCCAaAGtGGCTGTGGCcccaggaattataatgcttatctaCTGTTTCCATCTGTGAGGtagataagcattataattcctagGGAGGCAGCTcAaGGTCCGCCGCCGGAAACAGAGATGGGCTCC
[0063] miR26a1_all:SEQ ID NO:3
[0064] AGGGAATGAAGCCACAGGAGCCAAGAGCAGGAGGACCAAGGCCCTGGCGAtGGCCGTctCCTcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaGGGcgGCGGcCCaGaAaGCCGGCATCCGGGCTCAGGACCCCCCTCTCTGCCAGAGG
[0065] Let7a3_all: SEQ ID NO:4
[0066] TCTGGAAGCCACGGAGTCCCATCGGCACCAAGACCGtgTGCCCcTcGGcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaCTGcgGgGcacTAATAaCTGCGGTGGACAGAGCGTCTGGAACCCTGGCTGGGAGCGGGCAGG
[0067] Let7f1_All: SEQ ID NO:5
[0068] TCGAAAGAGATTGTACTTTCCATTCCAGAAGAcAACcTgGCTCTcTCcGcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaTGgcGAGagccCTTGCTGCATTATTTTCTTTTTATTTAGATG
[0069] Let7f2_All: SEQ ID NO:6
[0070] GATAGTTCCGAGTAGCTGGCCCACATAGGCTGAAGATaGcCcCTtGTGCTactcGGcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaCcgc GTGGTACtCTTCTTCTCCGACTGGCTCTGTTCAGGTTCTT
[0071] miR26b_All: SEQ ID NO:7
[0072] CCGTGCTGTGCTCCCTCGCCCCACCCTGcCCGGctCCCcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctagGGcGcCgGgcCCCccCtGCCTTGGGGTGAGGGGGCTGCCCCTGGATTCCTGC
[0073] Let7c_All: SEQ ID NO:8
[0074] TGCCATATTTGGAGGAGCTGACTGAAGATATGATAAGGAGTTTGAAGCAACATTGGAAaaTtgGTGgActCGGcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaTTGcgtCcacCTTcAagCGTCGAGGAATTCTTCATCACTTTAACCTGATTGAGCCAAT
[0075] Let7a2_All: SEQ ID NO:9
[0076] ATAAGACTAACTTGTAATTTCCCTGCTTAAGAAATGGTAGTTTTCCAGCCATTGaGACTtgATGCTCtCAGcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaTTGcGagcatCcCTAAACAACATGGTGAGAACGATCATGATTCCTCCAGGCCTTTTCTCC
[0077] Let7a1_Ring: SEQ ID NO:10
[0078] ACCATTCACCCTGGATGTTCTCTTCACTGTGGcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaCTAACGTGATAGAAAAGTCTGCATCCAGGCGGTC
[0079] Let7a3_Ring: SEQ ID NO:11
[0080] TCTGGAAGCCACGGAGTCCCATCGGCACCAAGACCGACTGCCCTTTGGcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctaCTGAAGTGGCTGTAATATCTGCGGTGGACAGAGCGTCTGGAACCCTGGCTGGGAGCGGGCAGG
[0081] Example 2: Novel artificial amiRNA supplementation experiment verifies GM
[0082] To further confirm the efficiency of the novel amiRNA in a system more akin to a therapeutic setting, the scaffolds were delivered in vitro into human induced pluripotent stem cell (hIPSC)-derived NGN2 neurons using rAAV vectors. Figure 4 shown.
[0083] The amiRNA was loaded with a leader / follower duplex targeting the gene PTEN, but as mentioned previously, nearly any gene can be targeted.
[0084] After rAAV infection, RNA and protein from NGN2 neurons were collected to assess: PTEN knockdown level at the protein level; PTEN knockdown level at the RNA level; amiRNA processing rate determined by quantification of residual GFP transcripts; amiRNA processing accuracy determined by small RNA sequencing; leader / follower ratio determined by small RNA sequencing.
[0085] Figure 5 It is shown how expression of all novel amiRNAs caused similar or stronger knockdown of PTEN protein compared to miRE and miR155.
[0086] PTEN knockdown levels at RNA level
[0087] Quantitative polymerase chain reaction (qPCR) showed how expression of all novel amiRNAs caused similar or stronger knockdown of PTEN mRNA compared to miRE and miR155. The results are shown in Tables 1 and Figure 6 shown.
[0088] Table 1
[0089]
[0090]
[0091] like Figure 6 As shown, qPCR experiments show that PTEN transcript levels are reduced due to the expression of amiRNA targeting PTEN transcripts. Three negative controls were included in the experiment: No amiRNA is cells infected with a virus expressing GFP but without amiRNA; Mock is untreated cells; Let7f2_WT is cells infected with unmodified amiRNA known not to cause any knockdown. The average of three independent biological replicates is plotted; error bars represent standard deviations; t-tests are performed to derive p-values compared to "mock" samples.
[0092] AmiRNA processing rates determined by quantification of residual GFP transcripts
[0093] The amiRNA is transcribed downstream of the GFP gene, producing a GFPmRNA-amiRNA hybrid transcript. After processing by DROSHA, the amiRNA is processed in the typical miRNA biosynthetic pathway (export to the cytoplasm, DICER processing, loading of the guide strand into the RISC complex, and target silencing). In contrast, the GFP portion of the transcript is rapidly degraded by cellular nucleases, such as Figure 7 shown.
[0094] Therefore, quantification of residual GFP transcripts is an indicator of the efficiency of DROSHA processing of a given amiRNA. High DROSHA processing ensures high downstream mature miRNA levels, ultimately leading to higher knockdown efficiency. Figure 8 and Table 2 show qPCR data for quantification of residual GFP transcripts; the data indicate that in most cases, novel amiRNAs are processed more efficiently than miREs and miR155.
[0095] Table 2
[0096]
[0097]
[0098] Accuracy of amiRNA processing determined by small RNA testing
[0099] An important feature of potent amiRNAs is the precision of processing by DROSHA and DICER. Indeed, imprecise processing may result in variations in the 5' ends of both guide and follower strands, leading to deviations from targeting and / or loading of the follower strand into RISC. Small RNA sequencing was used to investigate this important aspect of amiRNA processing, and as shown in the figures included in the "Processing precision" paper, all novel amiRNAs were accurately processed with >95% of guide strands starting from the correct 5' nucleotide. Importantly, the negative control Letf2WT showed a drastic reduction in mature guide strands starting from the correct 5' nucleotide, pointing to a difference from an efficient scaffold.
[0100] Leader / follower ratio determined by small RNA sequencing
[0101] After processing by DROSHA and DICER, only the guide strand should be loaded onto the RISC complex; the follower strand is rapidly degraded. In the case of amiRNAs, it is important to ensure that a large number of guide strands are detectable, while the follower strand should be detectable in much fewer copies. This aspect was assessed by small RNA sequencing, and while the number of guide strands detected was thousands to tens of thousands more than the number of follower strands, the number of follower strands was several-fold lower, at most only a few thousand reads, as shown in the normalized data in Table 3 and Figures 9a and 9b. This data complements and confirms the previous data on knockdown efficiency and processing precision and efficacy.
[0102] Table 3
[0103]
[0104] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0105] Although the present invention has been described in conjunction with various embodiments, it will be appreciated that the present invention is capable of further modification. This application is intended to cover any variation, use or modification of the present invention, generally following the principles of the present invention, and including deviations from the present disclosure within known and customary practices in the technical field to which the present invention belongs.
Claims
1. A method for generating amiRNA and modifying a selected primary miRNA, comprising: performing a base modification step to generate a single-stranded region of at least 9 nucleotides and the GU dinucleotides at positions -13 and -14, respectively, from the Drosha cleavage site to form a base modified construct; performing a base stem step to generate a double-stranded RNA having a CHC motif and a bulge at position +8 from the Drosha cleavage site to form a base stem modified construct; performing a loop modification step to replace the endogenous loop region of the primary miRNA with a loop of a miRE or another loop having the same number of nucleotides and a GUG motif at the same position to form a loop modified construct; and The base modification construct, the base stem modification construct and the loop modification construct are operably linked to the primary miRNA to form an amiRNA construct.
2. The method according to claim 1, wherein: The total length of the modified base stem ranged from 9 to 13 base pairs, with an optimal length of 11 base pairs.
3. The method of claim 2, further comprising examining the base modification construct, the basal stem modification construct, and the loop modification construct to form an expected structure. 4 . The method according to claim 3 , further comprising reducing the expression of PTEN mRNA by the amiRNA construct compared to miRE and miR155.
5. The method according to claim 4, wherein: The loop modification construct is a loop region having at least 75% sequence identity to SEQ ID NO: 3-9.
6. The method according to claim 5, wherein: The stem modification construct has at least 75% sequence identity to SEQ ID NO:
1.
7. The method according to claim 4, wherein: The loop region has at least 75% sequence identity with SEQ ID NOs: 10-11.
8. The method of claim 4, further comprising DROSHA and DICER of the amiRNA construct processing and detecting guide strands that are several thousand orders of magnitude more numerous than follower strands.
9. The method of claim 4, further comprising DROSHA processing and the amiRNA construct is processed more efficiently than miRE and miR155.
10. A heterologous or synthetic or artificial single-stranded ribonucleic acid (RNA) sequence comprising: (i) a selected primary miRNA and its complement, and (ii) a base region between the selected primary miRNA and its complement, wherein the nucleotide sequence of the base region has at least 75% sequence identity with SEQ ID NO:
1.
11. A heterologous or synthetic or artificial single-stranded ribonucleic acid (RNA) sequence comprising: (i) a selected primary-miRNA and its complement, and (ii) a base region and a basal stem between the selected primary-miRNA and the loop region, wherein the nucleotide sequences of the base region, the basal stem region and the loop region have at least 75% sequence identity with SEQ ID NO:3-9.
12. A heterologous or synthetic or artificial single-stranded ribonucleic acid (RNA) sequence comprising: (i) a selected primary miRNA and its complement, and (ii) a loop region linked to the selected primary miRNA, wherein the nucleotide sequence identity of the loop region has at least 75% sequence identity with SEQ ID No: 10-11.
13. A cell expressing: the RNA or its complementary sequence according to any one of claims 10-12; or the DNA or its complementary sequence according to claim 12; or the vector according to any one of claims 4-6.
14. The cell according to claim 13, wherein The RNA is processed into: the microRNA or its complementary sequence according to any one of claims 4-6; or the microRNA encoded by the DNA according to any one of claims 4-6.
